JP6599899B2 - 界面介在物を含む経皮送達システム - Google Patents

界面介在物を含む経皮送達システム Download PDF

Info

Publication number
JP6599899B2
JP6599899B2 JP2016568523A JP2016568523A JP6599899B2 JP 6599899 B2 JP6599899 B2 JP 6599899B2 JP 2016568523 A JP2016568523 A JP 2016568523A JP 2016568523 A JP2016568523 A JP 2016568523A JP 6599899 B2 JP6599899 B2 JP 6599899B2
Authority
JP
Japan
Prior art keywords
layer
phase
therapeutic system
active agent
transdermal therapeutic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2016568523A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017515872A (ja
JP2017515872A5 (enExample
Inventor
マルコ・アムゲンブロイヒ
ヨハネス・ヨーゼフ・レオンハルト
クリスチナ・カスナー
オレリア・ラパー
Original Assignee
エルテーエス ローマン テラピー−ジステーメ アーゲー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=50735940&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JP6599899(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by エルテーエス ローマン テラピー−ジステーメ アーゲー filed Critical エルテーエス ローマン テラピー−ジステーメ アーゲー
Publication of JP2017515872A publication Critical patent/JP2017515872A/ja
Publication of JP2017515872A5 publication Critical patent/JP2017515872A5/ja
Application granted granted Critical
Publication of JP6599899B2 publication Critical patent/JP6599899B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
    • A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
    • A61K9/7069—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained otherwise than by reactions only involving carbon to carbon unsaturated bonds, e.g. polysiloxane, polyesters, polyurethane, polyethylene oxide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
    • A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
    • A61K9/7053—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Inorganic Chemistry (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Anesthesiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Rheumatology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
JP2016568523A 2014-05-20 2015-05-20 界面介在物を含む経皮送達システム Active JP6599899B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP14169031 2014-05-20
EP14169031.3 2014-05-20
PCT/EP2015/061112 WO2015177212A1 (en) 2014-05-20 2015-05-20 Transdermal delivery system including an interface mediator

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2019181803A Division JP6820391B2 (ja) 2014-05-20 2019-10-02 界面介在物を含む経皮送達システム

Publications (3)

Publication Number Publication Date
JP2017515872A JP2017515872A (ja) 2017-06-15
JP2017515872A5 JP2017515872A5 (enExample) 2018-06-21
JP6599899B2 true JP6599899B2 (ja) 2019-10-30

Family

ID=50735940

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2016568523A Active JP6599899B2 (ja) 2014-05-20 2015-05-20 界面介在物を含む経皮送達システム
JP2019181803A Active JP6820391B2 (ja) 2014-05-20 2019-10-02 界面介在物を含む経皮送達システム

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2019181803A Active JP6820391B2 (ja) 2014-05-20 2019-10-02 界面介在物を含む経皮送達システム

Country Status (7)

Country Link
US (2) US11752110B2 (enExample)
EP (2) EP3145504B1 (enExample)
JP (2) JP6599899B2 (enExample)
CN (1) CN106456568B (enExample)
CA (1) CA2948221C (enExample)
ES (1) ES2954087T3 (enExample)
WO (1) WO2015177212A1 (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI687239B (zh) * 2015-10-26 2020-03-11 日商久光製藥股份有限公司 貼附劑
CN115813888A (zh) 2016-12-20 2023-03-21 罗曼治疗系统股份公司 包含阿塞那平的透皮治疗系统
CA3047354A1 (en) 2016-12-20 2018-06-28 Lts Lohmann Therapie-Systeme Ag Transdermal therapeutic system containing asenapine and polysiloxane or polyisobutylene
JP2020525545A (ja) 2017-06-26 2020-08-27 エルテーエス ローマン テラピー−ジステーメ アーゲー アセナピンおよびシリコーンアクリルハイブリッドポリマーを含有する経皮治療システム
CN118806732A (zh) 2018-06-20 2024-10-22 罗曼治疗系统股份公司 含有阿塞那平的透皮治疗系统
JP7502199B2 (ja) 2018-06-20 2024-06-18 エルテーエス ローマン テラピー－ジステーメ アーゲー アセナピンを含有する経皮治療システム
KR102710072B1 (ko) * 2018-08-31 2024-09-24 에스케이케미칼 주식회사 장기 투여용 리바스티그민 패취
JP7399633B2 (ja) * 2019-06-14 2023-12-18 株式会社大石膏盛堂 経皮吸収型製剤の製造方法
JP2023553010A (ja) 2020-12-03 2023-12-20 バテル・メモリアル・インスティテュート 非ウイルス性送達のためのポリマーナノ粒子およびｄｎａナノ構造組成物ならびに方法
WO2022216977A1 (en) 2021-04-07 2022-10-13 Batelle Memorial Institute Rapid design, build, test, and learn technologies for identifying and using non-viral carriers
WO2025072751A1 (en) 2023-09-29 2025-04-03 Battelle Memorial Institute Polymer nanoparticle compositions for in vivo expression of polypeptides
WO2025122954A1 (en) 2023-12-08 2025-06-12 Battelle Memorial Institute Use of dna origami nanostructures for molecular information based data storage systems

Family Cites Families (79)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3315272C2 (de) 1983-04-27 1986-03-27 Lohmann Gmbh & Co Kg, 5450 Neuwied Pharmazeutisches Produkt und Verfahren zu seiner Herstellung
US4906463A (en) * 1986-12-22 1990-03-06 Cygnus Research Corporation Transdermal drug-delivery composition
US5405486A (en) 1988-03-04 1995-04-11 Noven Pharmaceuticals, Inc. Apparatus for forming a transdermal drug device
US5474783A (en) 1988-03-04 1995-12-12 Noven Pharmaceuticals, Inc. Solubility parameter based drug delivery system and method for altering drug saturation concentration
US4994267A (en) 1988-03-04 1991-02-19 Noven Pharmaceuticals, Inc. Transdermal acrylic multipolymer drug delivery system
US5719197A (en) 1988-03-04 1998-02-17 Noven Pharmaceuticals, Inc. Compositions and methods for topical administration of pharmaceutically active agents
US5656286A (en) 1988-03-04 1997-08-12 Noven Pharmaceuticals, Inc. Solubility parameter based drug delivery system and method for altering drug saturation concentration
US5300291A (en) 1988-03-04 1994-04-05 Noven Pharmaceuticals, Inc. Method and device for the release of drugs to the skin
US5032207A (en) 1988-03-04 1991-07-16 Noven Pharmaceuticals, Inc. One-step method for forming a pressure-sensitive adhesive transdermal drug device
US4814168A (en) 1988-03-04 1989-03-21 Noven Pharmaceuticals, Inc. Transdermal multipolymer drug delivery system
US4994278A (en) 1988-03-04 1991-02-19 Noven Pharmaceuticals, Inc. Breathable backing
DK0474647T3 (da) 1990-03-28 1997-08-18 Noven Pharma Fremgangsmåde og indretning til frigivelse af lægemidler til huden
AU2004092A (en) 1991-04-25 1992-12-21 Noven Pharmaceuticals, Inc. Method and apparatus for forming a transdermal drug device
US5387189A (en) 1993-12-02 1995-02-07 Alza Corporation Electrotransport delivery device and method of making same
DE19814084B4 (de) 1998-03-30 2005-12-22 Lts Lohmann Therapie-Systeme Ag D2-Agonist enthaltendes transdermales therapeutisches System zur Behandlung des Parkinson-Syndroms und Verfahren zu seiner Herstellung
US6757560B1 (en) 1999-04-09 2004-06-29 Novosis Pharma Ag Transdermal delivery system (TDS) with electrode network
US7655249B2 (en) 1998-09-30 2010-02-02 Corixa Corporation Compositions and methods for WT1 specific immunotherapy
US6317630B1 (en) 1999-01-29 2001-11-13 Yossi Gross Drug delivery device
ES2260021T3 (es) 1999-06-08 2006-11-01 Altea Therapeutics Corporation Aparatos para la microporacion de membranas biologicas utilizando dispositivos de interfaz de tejido de pelicula delgada, y su metodo.
BR0012152A (pt) 1999-07-02 2002-03-12 Lohmann Therapie Syst Lts Sistema de microrreservatórios na base de polissiloxanos e solventes ambifìlicos
DE10012908B4 (de) 2000-03-16 2005-03-17 Lts Lohmann Therapie-Systeme Ag Stabilisierte übersättigte transdermale therapeutische Matrixsysteme und Verfahren zu ihrer Herstellung
DE10041479A1 (de) 2000-08-24 2002-03-14 Sanol Arznei Schwarz Gmbh Neue pharmazeutische Zusammensetzung zur Verabreichung von N-0923
US6682757B1 (en) 2000-11-16 2004-01-27 Euro-Celtique, S.A. Titratable dosage transdermal delivery system
EP1381358B1 (en) 2001-04-02 2006-05-03 Astrazeneca AB Solid pharmaceutical composition comprising 4'-cyano-trifluoro-3-(4-fluorophenylsulphonyl) -2-hydroxy-2-methylpropiono- m toluidide and pvp
DE10118282A1 (de) 2001-04-12 2002-12-05 Lohmann Therapie Syst Lts Haftkleber auf Basis von Ethylen-Vinylacetat-Copolymeren und Klebharzen, für medizinische Verwendungszwecke
US20030026830A1 (en) 2001-05-08 2003-02-06 Thomas Lauterback Transdermal therapeutic system for parkinson's disease inducing high plasma levels of rotigotine
ATE251901T1 (de) 2001-05-08 2003-11-15 Sanol Arznei Schwarz Gmbh Transdermales therapeutisches system für die erzielung hoher plasmaspiegel von rotigotin in der therapie von morbus parkinson
DK1256340T3 (da) 2001-05-08 2003-12-01 Sanol Arznei Schwarz Gmbh Forbedret transdermalt, terapeutisk system til behandlingen af Parkinsons sygdom
DE10141651B4 (de) 2001-08-24 2007-02-15 Lts Lohmann Therapie-Systeme Ag Transdermales Therapeutisches System (TTS) mit dem Wirkstoff Fentanyl und Verfahren zu seiner Herstellung
EP1453447A4 (en) * 2001-08-17 2006-06-07 Lavipharm Lab Inc COMPOSITION AND DEVICE FOR TRANSDERMAL DRUG DELIVERY
DE10159745A1 (de) 2001-12-05 2003-07-03 Lohmann Therapie Syst Lts Transdermales Therapeutisches System mit verbessertem Langzeittragekomfort
US6775570B2 (en) 2002-02-04 2004-08-10 Ceramatec, Inc. Iontophoretic treatment device
US20030180281A1 (en) * 2002-03-11 2003-09-25 Bott Richard R. Preparations for topical skin use and treatment
US20060263419A1 (en) 2002-03-12 2006-11-23 Hans-Michael Wolff Transdermal therapeutic system for Parkinson's Disease
DE10220230A1 (de) 2002-05-06 2003-11-27 Sanol Arznei Schwarz Gmbh Verwendung von Rotigotine zur Behandlung des Restless Leg Syndroms
EP1386605A1 (en) 2002-07-30 2004-02-04 Schwarz Pharma Ag Improved transdermal delivery system for the administration of rotigotine
DE10234673B4 (de) 2002-07-30 2007-08-16 Schwarz Pharma Ag Heißschmelz-TTS zur Verabreichung von Rotigotin und Verfahren zu seiner Herstellung sowie Verwendung von Rotigotin bei der Herstellung eines TTS im Heißschmelzverfahren
EP1386604A1 (en) * 2002-07-30 2004-02-04 Schwarz Pharma Ag Improved transdermal delivery system
US8246979B2 (en) 2002-07-30 2012-08-21 Ucb Pharma Gmbh Transdermal delivery system for the administration of rotigotine
US8211462B2 (en) 2002-07-30 2012-07-03 Ucb Pharma Gmbh Hot-melt TTS for administering rotigotine
DK1426049T3 (da) 2002-12-02 2005-08-22 Sanol Arznei Schwarz Gmbh Iontophoretisk tilförsel af rotigotin til behandling af Parkinsons sygdom
DE10261696A1 (de) 2002-12-30 2004-07-15 Schwarz Pharma Ag Vorrichtung zur transdermalen Verabreichung von Rotigotin-Base
CN100403477C (zh) 2003-01-02 2008-07-16 Cymbet公司 固态电池供电装置及其制造方法
US7603144B2 (en) 2003-01-02 2009-10-13 Cymbet Corporation Active wireless tagging system on peel and stick substrate
BRPI0318250B8 (pt) 2003-04-14 2021-05-25 Lts Lohmann Therapie Systeme Ag emplastro tópico com matriz de polissiloxano e método para a produção de preparação de um emplastro tópico
WO2005009417A1 (en) 2003-07-21 2005-02-03 Noven Pharmaceuticals, Inc. Composition and method for controlling grug delivery from silicone adhesive blends
DE10334188B4 (de) 2003-07-26 2007-07-05 Schwarz Pharma Ag Verwendung von Rotigotin zur Behandlung von Depressionen
EP1547592A1 (en) 2003-12-23 2005-06-29 Schwarz Pharma Ag Intranasal formulation of rotigotine
DE10361259A1 (de) 2003-12-24 2005-07-28 Schwarz Pharma Ag Verwendung von Rotigotine in einem Frühstadium von Morbus Parkinson zur Prävention des weiteren Neuronenverlustes
US20050202073A1 (en) 2004-03-09 2005-09-15 Mylan Technologies, Inc. Transdermal systems containing multilayer adhesive matrices to modify drug delivery
US9205062B2 (en) 2004-03-09 2015-12-08 Mylan Pharmaceuticals, Inc. Transdermal systems containing multilayer adhesive matrices to modify drug delivery
DE102004014841B4 (de) 2004-03-24 2006-07-06 Schwarz Pharma Ag Verwendung von Rotigotin zur Behandlung und Prävention des Parkinson-Plus-Syndroms
WO2005119610A1 (en) 2004-05-28 2005-12-15 Jan De Geest Communication unit for a person's skin
JP2006178807A (ja) 2004-12-24 2006-07-06 Echigo Fudagami Kk Ｉｃシート製造装置及びｉｃシート製造方法
GB0506139D0 (en) 2005-03-24 2005-05-04 Transphase Ltd A transdermal topical composition and its uses
TWI389709B (zh) 2005-12-01 2013-03-21 Novartis Ag 經皮治療系統
DE102006054731B4 (de) * 2006-11-21 2013-02-28 Lts Lohmann Therapie-Systeme Ag Transdermales therapeutisches System zur Verabreichung des Wirkstoffs Buprenorphin und Verwendung desselben in der Schmerztherapie
DE102006054733A1 (de) 2006-11-21 2008-05-29 Lts Lohmann Therapie-Systeme Ag Transdermales therapeutisches Systems mit hoher Wirkstoffausnutzungsrate und Dosiergenauigkeit
CN101147739B (zh) 2007-07-06 2010-12-08 北京康倍得医药技术开发有限公司 含罗替戈汀的组合物及其制药用途以及含该组合物的透皮贴剂
JP2010536434A (ja) 2007-08-17 2010-12-02 イシス バイオポリマー エルエルシー イオン泳動薬物送達システム
EP2190430A1 (de) 2007-08-24 2010-06-02 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Verwendung von von cycloheximid abgeleiteten verbindungen zur behandlung oder vorbeugung von insbesondere ischämien und herzerkrankungen
UY31406A1 (es) 2007-10-19 2009-05-29 "producto de dispersion solida que contiene un compuesto a base de n-aril urea".
SI2215072T1 (sl) 2007-11-28 2015-10-30 Ucb Pharma Gmbh Polimorfna oblika rotigotina
AU2009262871B2 (en) 2008-05-30 2016-04-14 Mylan Inc. Stabilized transdermal drug delivery system
JP2009297808A (ja) 2008-06-11 2009-12-24 Chiyoda Integre Co Ltd 粘着テープ製造方法及び粘着テープ製造装置
EP2140861A1 (en) 2008-06-30 2010-01-06 Abbott GmbH & Co. KG Pharmaceutical dosage form comprising polymeric carrier composition
AR074047A1 (es) 2008-09-09 2010-12-22 Transcu Ltd Sistemas, dispositivos, y metodos para suministrar energia a dispositivos, por ejemplo dispositivos de administracion transdermica y/o para controlarlos
EP2349230A2 (en) 2008-10-06 2011-08-03 Mylan Technologies, Inc. Amorphous rotigotine transdermal system
WO2010129928A1 (en) 2009-05-08 2010-11-11 Isis Biopolymer Llc Iontophoretic device with improved counterelectrode
EP2281559A1 (en) 2009-06-26 2011-02-09 UCB Pharma GmbH Pharmaceutical composition comprising rotigotine salts (acid or Na), especially for iontophoresis
DE102009052972A1 (de) 2009-11-12 2011-09-15 Lts Lohmann Therapie-Systeme Ag Verfahren zur Verhinderung der Kristallisation von Arzneistoffen in einem Polymerfilm
KR20160055971A (ko) 2009-12-22 2016-05-18 유씨비 파르마 게엠베하 비결정질형 로티고틴의 고체 분산체의 안정화를 위한 폴리비닐피롤리돈
BR112013012117A8 (pt) 2010-11-23 2017-10-10 Nupathe Inc Sistema de distribuição de fármaco iontoforético coempacotado de utilização única coempacotado autocontido, usos de fármaco e de composto de triptano
WO2012084969A1 (en) 2010-12-22 2012-06-28 Hexal Ag Adhesive composition containing rotigotine and transdermal therapeutic system comprising the adhesive composition
DE102012013421A1 (de) 2012-07-03 2014-01-09 Alfred E. Tiefenbacher (Gmbh & Co. Kg) Transdermales therapeutisches System (TTS) mit Rotigotin
WO2013075823A1 (en) 2011-11-22 2013-05-30 Alfred E. Tiefenbacher (Gmbh & Co. Kg) Transdermal therapeutic system comprising rotigotine and crystallization inhibitor
EP2790685B1 (en) * 2011-12-12 2017-08-16 LTS LOHMANN Therapie-Systeme AG Transdermal delivery system comprising buprenorphine
TW201431570A (zh) * 2012-11-22 2014-08-16 Ucb Pharma Gmbh 用於經皮投服羅替戈汀（Ｒｏｔｉｇｏｔｉｎｅ）之多天式貼片
LT2810646T (lt) 2013-06-04 2016-10-25 Lts Lohmann Therapie-Systeme Ag Transderminė tiekimo sistema

Also Published As

Publication number Publication date
JP6820391B2 (ja) 2021-01-27
CN106456568A (zh) 2017-02-22
EP3145504B1 (en) 2023-07-26
CA2948221C (en) 2022-11-22
JP2017515872A (ja) 2017-06-15
EP4238580A3 (en) 2023-10-25
CN106456568B (zh) 2020-03-27
BR112016027148A8 (pt) 2021-06-29
US20180221300A1 (en) 2018-08-09
US11752110B2 (en) 2023-09-12
CA2948221A1 (en) 2015-11-26
WO2015177212A1 (en) 2015-11-26
EP3145504C0 (en) 2023-07-26
JP2020019788A (ja) 2020-02-06
US20240016757A1 (en) 2024-01-18
BR112016027148A2 (pt) 2017-08-15
EP3145504A1 (en) 2017-03-29
ES2954087T3 (es) 2023-11-20
EP4238580A2 (en) 2023-09-06
US12427119B2 (en) 2025-09-30

Similar Documents

Publication Publication Date Title
JP6599899B2 (ja) 界面介在物を含む経皮送達システム
US20230248661A1 (en) Transdermal Delivery System Containing Rotigotine
JP6895755B2 (ja) 経皮送達システムにおける活性薬剤の放出を調節するための方法
JP6301356B2 (ja) ロチゴチンの経皮投与のための複数日用のパッチ
JP7660162B2 (ja) シリコーンポリマーを含むグアンファシンの経皮投与のための経皮治療システム
KR102776309B1 (ko) 적어도 하나의 첨가제를 포함하는 구안파신의 경피 투여용 경피흡수 치료 시스템
JP2020532582A (ja) リバスチグミンの経皮投与のための経皮治療システム
HK40100478A (en) Transdermal delivery system including an interface mediator
JP2020525546A (ja) スコポラミン及びシリコーンアクリルハイブリッドポリマーを含有する経皮治療システム
HK1236096B (en) Transdermal delivery system including an interface mediator
HK1236096A1 (en) Transdermal delivery system including an interface mediator
HK40011528B (en) Multi-day patch for the transdermal administration of rotigotine
HK1236094B (en) Transdermal delivery system containing rotigotine
HK1236094A1 (en) Transdermal delivery system containing rotigotine
HK40034304B (zh) 用於透皮施用胍法辛的包含至少一种添加剂的透皮治疗系统
HK40028675A (en) Transdermal therapeutic system for the transdermal administration of rivastigmine
HK40024535A (en) Transdermal therapeutic system containing scopolamine and silicone acrylic hybrid polymer
BR112016027148B1 (pt) Sistema terapêutico transdérmico para administração transdérmica de rotigotina, seu uso, seu método de fabricação, uso de um óleo de silicone, e método para fabricação de uma camada bifásica seca contendo agente ativo

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180511

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20180511

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20190116

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20190129

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190417

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20190507

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190731

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20190903

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20191003

R150 Certificate of patent or registration of utility model

Ref document number: 6599899

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250